For immunochemical detection of sEH
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Soluble Epoxide Hydrolase Polyclonal Antibody

Item No. 10010146

Technical Information
Synonyms
  • Cytosolic Epoxide Hydrolase (CEH)
  • EPHX2
  • Epoxide Hydrolase 2
  • sEH
Immunogen
Synthetic peptide from the internal region of human sEM
500 μl of peptide affinity-purified polyclonal antibody
Storage Buffer
PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
Host
Rabbit
Applications
WB
Species Reactivity
(+) Human(+) Mouse(+) Rat
UniProt Accession №
P34913
Origin
Animal/Rabbit
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Soluble epoxide hydrolase (sEH) is a member of the α/β-hydrolase fold enzyme family that catalyzes the hydrolysis of bioactive fatty acid epoxides to inactive vicinal diols.1 It is a homodimer in which each subunit is composed of two domains, a C-terminal epoxide hydrolase domain and an N-terminal phosphatase domain.2,3 sEH is localized to the cytoplasm or to peroxisomes in a tissue-specific manner and is found in various tissues, including skin, lung, uterus, kidney, brain, and myocardium.4,5 sEH is also expressed in the vasculature and inhibition of sEH attenuates pathogenic vascular remodeling and hypertension via preservation of cardioprotective epoxyeicosatrienoic acids (EETs) in rat models of atherosclerosis and hypertension, respectively.6 Inhibition of sEH also has a protective role in various diseases, including inflammatory bowel disease, osteoarthritis, seizure, stroke, and Alzheimer’s disease, as well as in various chronic pain states.1,7 Cayman’s Soluble Epoxide Hydrolase Polyclonal Antibody can be used for Western blot. The antibody recognizes sEH at approximately 64 kDa from human, mouse, and rat samples.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Harris, T.R., and Hammock, B.D. Soluble epoxide hydrolase: Gene structure, expression and deletion. Gene 526(2), 61-74 (2013).

    2. Cronin, A., Mowbray, S., Dürk, H., et alThe N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc. Natl. Acad. Sci. USA 100(4), 1552-1557 (2002).

    3. Chiamvimonvat, N., Ho, C.M., Tsai, H.J., et alThe soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 50(3), 225-237 (2007).

    4. Enayetallah, A.E., French, R.A., Barber, M., et alCell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J. Histochem. Cytochem. 54(3), 329-335 (2006).

    5. Domingues, M.F., Callai-Silva, N., Piovesan, A.R., et alSoluble epoxide hydrolase and brain cholesterol metabolism. Front. Mol. Neurosci. 12, 325 (2020).

    6. Simpkins, A.N., Rudic, R.D., Roy, S., et alSoluble epoxide hydrolase inhibition modulates vascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 298(3), H795-H806 (2009).

    7. Wagner, K.M., McReynolds, C.B., Schmidt, W.K., et alSoluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol. Ther. 180, 62-76 (2017).